Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living South Dakota.
Press releases published on July 2, 2025
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
GlobeNewswire
·
July 2, 2025
- 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug development company …
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
GlobeNewswire
·
July 2, 2025
OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that following the hearing on June 24th, 2025, the President of the Nantes Commercial …
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
GlobeNewswire
·
July 2, 2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 2 juillet 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience du mardi 24 juin 2025, le Président du …
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch
GlobeNewswire
·
July 2, 2025
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch Comprehensive clinical performance study encompassed 646 participant visits, including both Type 2 diabetic patients and healthy volunteers …
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
GlobeNewswire
·
July 2, 2025
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop novel ansamycin leads from BioVersys’ …
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
·
July 2, 2025
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing …